In both these examples, properties of the vaccine appear to violate the usual rules of CD8+ T cell priming and both show promising efficacy in the SIV-macaque model, suggesting novel ways in which vaccines may avoid the evolutionary solutions that SIV/HIV may have developed in natural infection. The gene discussed is CD8A; the disease is infection.